looking to buy some GALE, anyone w/ thoughts on this?
Phase 3 enrollement and P2 had good numbers. getting interested in it. it stops recurrence rate for breast cancer from 25 percent to 5 percent. probably need to hold for 1 to 2 years imo for to go quadriple imo.
of course there are risks as dilution for small pharma, but seems good. any longs that have this while we wait for QCOR earnings?
OR just maybe QCOR should buy it for its pipeline. why not?
GALE's 10K indicates that phase III trials began some time in H1 2012. trials are 36 months, then they have the NDA to get approved, after that they have to assemble a sales force, sales take time to gain momentum, market makers sell positions into the rally.then, a year or so later you have the whistle blower lawsuit, the United States Attorney's office to file their extortion claim and the subsequent bear raid by the market makers.